Development of Pharmacophore Alignment Models as Input for Comparative Molecular Field Analysis of a Diverse Set of Azole Antifungal Agents

Journal of Chemical Information and Computer Sciences

Volumn 39, Issue 6, 1999, Pages 958-966

  Talele, Tanaji T ^a   Kulkarni, Santosh S ^a   Kulkarni, Vithal M ^a  

^a UNIVERSITY OF MUMBAI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001589603     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci990020o     Document Type: Article

References (35)

1. Tafi, A.; Anastassopoulou, J.; Theophanides, T.; Botta, M.; Corelli, F.; Massa, S.; Artico, M.; Costi, R.; Di Santo, R.; Ragno, R. Molecular Modeling of Azole Antifungal Agents Active Against Candida albicans. 1. A Comparative Molecular Field Analysis Study. J. Med. Chem. 1996, 39, 1227-1235.
2. Hitchcock, C. A.; Dickinson, K.; Brown, S. B.; Evans, E. G. V.; Adams, D. J. Interaction of Azole Antifungal Antibiotics with Cytochrome P-450 Dependent 14 α-Sterol Demethylase Purified from Candida albicans. Biochem. J. 1990, 206, 475-480.
3. 14αDM Purified from Saccharomyces cerevisiae Microsomes. Biochem. Pharmacol. 1987, 36, 229-235.
4. Goldman, R. C.; Klein, L. L. Problems and Progress in Opportunistic Infections. In Annual Reports in Medicinal Chemistry; Bristol, A. J., Ed.; Academic Press: San Diego, CA, 1994; Vol. 29, pp 155-164.
5. Odds, F. C.; Schmid, J.; Soll, D. R. Epidemiology of Candida Infections in AIDS. In Mycoses in AIDS Patients; Vanden Bossche, H., Ed.; Plenum Press: New York, 1990; pp 67-74.
6. Golender, V.; Vorpagel, E. In 3D QSAR in Drug Design: Theory, Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, The Netherlands, 1993; pp 137-149.
7. Van de Waterbeemd, H. In Advanced Computer-Assisted Techniques in Drug Discovery; Van de Waterbeemd, H., Ed.; VCH Publishers: New York, 1994; Vol. 3.
8. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA) 1. Effect of Shape in Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
9. Fromtling, R. A. Drugs Future 1985, 10, 983-984.
10. Sammes, P. G. In Topics in Antibiotic Chemistry; Sammes, P. G., Ed.; Ellis Horwood Ltd.: Chichester, U.K., 1982; Vol. 6, Chapter 1, pp 22-97.
11. Drugs Future 1981, 6, 444-445.
12. Drugs Future 1988, 13, 624-626.
13. Benfield, P.; Clissold, S. P. Sulconazole: A Review of Its Antimicrobial Activity and Therapeutic Use in Superficial Dermatomycoses. Drugs 1988, 35, 143-153.
14. Xavier, R.; Hopkins, S. J. Neticonazole: A New and Highly Active Imidazole Antifungal agent. Drugs Today 1994, 30, 497-505.
15. Plempel, M.; Regel, E.; Buchel, K. H. Antimycotic Efficacy of Bifonazole in Vitro and in Vivo. Arzneim.-Forsch. 1983, 33, 517-524.
16. Bartoli, J.; Alguero, M.; Boncomte, E.; Forn, J. Synthesis and Antifungal Activity of a Series of Difluorotritylimidazoles. Arzneim.-Forsch. 1992, 42, 832-835.
17. Michel, G. Drugs Today 1993, 29, 307-310.
18. Walker, K. A. M.; Braemer, A. C.; Hitt, S.; Jones, R. E.; Matthews, T. R. 1-[4-(4-Chlorophenyl)-2-(2,6-dichlorophenylthio)-n-butyl]-1H-imidazole Nitrate, a New Potent Antifungal Agent. J. Med. Chem. 1978, 21, 840-842.
19. Drugs Future 1996, 21, 160-166.
20. Veronese, M.; Salvaterra, M.; Barzaghi, D. Fenticonazole: A New Imidazole derivative with Antibacterial and Antifungal Activity. Arzneim.-Forsch. 1981, 31, 2133-2137.
21. Rane, D. F.; Desai, J. A.; Pike, R. E. 2-Azolylmethyl-3-difluorobenzyloxy-2,3-dihydrofluorobenzo[b]thiophenes and compositions containing them. Chem. Abstr. 1986, 105, P152918e.
22. Fromtling, R. A. Drugs Future 1985, 10, 293-294.
23. Drouhnet, E.; Dupont, B. Drugs Future 1996, 21, 160-166.
24. INSIGHT II (Version 97.0), October, 1995; Molecular Simulations Inc.: San Diego, CA, 1995.
25. SYBYL (Version 6.22) Molecular Modeling System; Tripos Associates Inc.: St. Louis, MO, 1995.
26. 14αDM Inhibiting Azole Antifungal Agents. J. Chem. Inf. Comput. Sci. 1999, 39, 204-210.
27. Hariprasad, V.; Kulkarni, V. M. A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists. J. Comput.-Aided Mol. Des. 1996, 10, 284-292.
28. Stahle, L.; Wold, S. Partial Least Squares Analysis with Cross-Validation for the Two-Class Problem: A Monte Carlo Study. J. Chemom. 1987, 1, 185-196.
29. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E.; Frank, I. E. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
30. Greco, G.; Novellino, E.; Silipo, C.; Vittoria, A. Comparative Molecular Field Analysis on a Set of Muscarinic Agonists. Quant. Struct.-Act. Relat. 1991, 10, 289-299.
31. a's) of Clonidine-like Imidazolines, 2-Substituted Imidazoles, and 1-Methyl-3-substituted Imidazoles from 3D Structures Using a Comparative Molecular Field Analysis (CoMFA). J. Med. Chem. 1991, 34, 2056-2060.
32. Kulkarni, S. S.; Kulkarni, V. M. Three-Dimensional Quantitative Stricture-Activity Relationship of Interleukin 1-β Converting Enzyme Inhibitors: A Comparative Molecular Field Analysis Study. J. Med. Chem. 1999, 42, 373-380.
33. Dewar, M. J. S. E.; Zoebisch, G.; Healy, E. F. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
34. Folkers, G.; Merz, A.; Rognan, D. CoMFA: Scope and limitations. In 3D QSAR in drug design; Kubinyi, H., Ed.; Escom: Leiden, The Netherlands, 1993; pp 583-618.
35. 14αDM Inhibiting Azole Antifungals. Drug Des. Discovery 1998, 15, 181-190.